To include your compound in the COVID-19 Resource Center, submit it here.

RNA BiTEs

BioNTech creates cancer bispecifics from mRNA.

BioNTech AG believes its RNA therapeutics platform can produce bispecific antibodies that circumvent the manufacturing and short plasma half-life problems of other technologies, and thinks its approach can accelerate the development timeline for bispecific T cell-engaging antibodies (BiTEs) in cancer.

In June, the company published a study in Nature Medicine demonstrating RNA injection could produce functional levels of a bispecific antibody in mice with a better PK profile and less frequent dosing than its

Read the full 739 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE